[
  {
    "ts": null,
    "headline": "Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update",
    "summary": "BOSTON, December 08, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVY™ (exagamglogene autotemcel) from global clinical trials in people with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). CASGEVY is the first and only approved CRISPR/Cas9 gene-edited therapy.",
    "url": "https://finnhub.io/api/news?id=7b0a21220cc37e0e0ec0aaefc75b809a5ed708c217768a27532e029d299e822d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733680320,
      "headline": "Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update",
      "id": 131865411,
      "image": "https://media.zenfs.com/en/business-wire.com/85e57414269c09f303f84023b4554278",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "BOSTON, December 08, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVY™ (exagamglogene autotemcel) from global clinical trials in people with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). CASGEVY is the first and only approved CRISPR/Cas9 gene-edited therapy.",
      "url": "https://finnhub.io/api/news?id=7b0a21220cc37e0e0ec0aaefc75b809a5ed708c217768a27532e029d299e822d"
    }
  }
]